Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 11, 2008, Pages 4181-4183

  Garcia Effron, Guillermo ^a   Kontoyiannis, Dimitrios P ^b   Lewis, Russell E ^b   Perlin, David S ^a  

^a PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; CASPOFUNGIN; FLUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; VORICONAZOLE;

ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AMINO ACID SUBSTITUTION; ARTICLE; CANDIDA TROPICALIS; CANDIDEMIA; CASE REPORT; DNA SEQUENCE; DRUG WITHDRAWAL; FUNGUS MUTATION; HODGKIN DISEASE; HUMAN; IC 50; IMMUNOCOMPROMISED PATIENT; LARGE CELL LYMPHOMA; MALE; MINIMUM INHIBITORY CONCENTRATION; NEUTROPENIA; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; CANDIDA TROPICALIS; CANDIDIASIS; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; FUNGEMIA; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; MIDDLE AGED;

EID: 55849137651     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00802-08     Document Type: Article

References (16)

1. Balashov, S. V., S. Park, and D. S. Perlin. 2006. Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1. Antimicrob. Agents Chemother. 50:2058-2063.
2. Chou, L. S., R. E. Lewis, C. Ippoliti, R. E. Champlin, and D. P. Kontoyiannis. 2007. Caspofungin as primary antifungal prophylaxis in stem cell transplant recipients. Pharmacotherapy 27:1644-1650.
3. Cleary, J. D., G. Garcia-Effron, S. W. Chapman, and D. S. Perlin. 2008. Reduced Candida glabrata susceptibility secondary to a FKS1 mutation developed during candidemia treatment. Antimicrob. Agents Chemother. 52:2263-2265.
4. Denning, D. W. 2003. Echinocandin antifungal drugs. Lancet 362:1142-1151.
5. Garcia-Effron, G., S. K. Katiyar, S. Park, T. D. Edlind, and D. S. Perlin. 2008. A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. Antimicrob. Agents Chemother. 52:2305-2312.
6. Kahn, J. N., G. Garcia-Effron, M. J. Hsu, S. Park, K. A. Marr, and D. S. Perlin. 2007. Acquired echinocandin resistance in a Candida krusei isolate due to modification of glucan synthase. Antimicrob. Agents Chemother. 51:1876-1878.
7. Kartsonis, N., J. Killar, L. Mixson, C. M. Hoe, C. Sable, K. Bartizal, and M. Motyl. 2005. Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcome. Antimicrob. Agents Chemother. 49:3616-3623.
8. Katiyar, S., M. Pfaller, and T. Edlind. 2006. Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility. Antimicrob. Agents Chemother. 50:2892-2894.
9. Kontoyiannis, D. P., I. Vaziri, H. A. Hanna, M. Boktour, J. Thornby, R. Hachem, G. P. Bodey, and I. I. Raad. 2001. Risk Factors for Candida tropicalis fungemia in patients with cancer. Clin. Infect. Dis. 33:1676-1681.
10. National Committee for Clinical Laboratory Standards. 2002. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A2, 2nd ed. National Committee for Clinical and Laboratory Standards, Wayne, PA.
11. Park, S., R. Kelly, J. N. Kahn, J. Robles, M. J. Hsu, E. Register, W. Li, V. Vyas, H. Fan, G. Abruzzo, A. Flattery, C. Gill, G. Chrebet, S. A. Parent, M. Kurtz, H. Teppler, C. M. Douglas, and D. S. Perlin. 2005. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob. Agents Chemother. 49:3264-3273.
12. Pasquale, T., J. R. Tomada, M. Ghannoun, J. Dipersio, and H. Bonilla. 2008. Emergence of Candida tropicalis resistant to caspofungin. J. Antimicrob. Chemother. 61:219.
13. Perlin, D. S. 2007. Resistance to echinocandin-class antifungal drugs. Drug Resist. Updat. 10:121-130.
14. Pfaller, M. A., L. Boyken, R. J. Hollis, J. Kroeger, S. A. Messer, S. Tendolkar, and D. J. Diekema. 2008. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J. Clin. Microbiol. 46:150-156.
15. van Burik, J. A., V. Ratanatharathorn, D. E. Stepan, C. B. Miller, J. H. Lipton, D. H. Vesole, N. Bunin, D. A. Wall, J. W. Hiemenz, Y. Satoi, J. M. Lee, and T. J. Walsh. 2004. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin. Infect. Dis. 39:1407-1416.
16. White, T. J., T. D. Bruns, S. B. Lee, and J. W. Taylor. 1990. Amplification and direct sequencing of fungal ribosomal RNA genes for phylogenetics, p. 315-322. In: M. A. Innis, D. H. Gelfand, J. J. Sninsky, and T. J. White (ed.), PCR protocols: a guide to methods and applications. Academic Press, Inc., San Diego, CA.